Aarti Pharmalabs Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Revenue down, margin up: Revenue declined slightly on lower Xanthine derivative prices, yet EBITDA margin improved because raw material costs fell faster than finished product prices.
• Xanthine is the swing factor: Softening caffeine and Xanthine pricing, expanded capacity, and falling raw material costs are all being managed to hold contribution margins, with backward integration arriving as supply insurance rather than a margin lever.
• New assets are loading: The new API block targets 70% utilization in FY25, nine hydrogen reactors are operational, and a semi-commercial block in Vapi aims for Q2 FY25 completion, setting up a CAPEX benefit ramp starting H2.
• Subsidiary strength offset standalone flatness: Consolidated revenue decline partly reflects a subsidiary being ramped down for transfer; the 50-50 joint venture delivered strong numbers and stable business is expected this year.
• What to watch next quarter: Whether the Xanthine backward integration project begins operations on schedule, the pace of new product validations in the multi-purpose block, and any stabilization in API dispatch timing.

Xanthine Derivatives: Pricing, Capacity & Backward Integration

• Revenue headwind: Top-line degrowth was driven by the Xanthine segment, where final product prices have declined over the last two quarters, though raw material prices also reduced simultaneously.
• Margin resilience: EBITDA margin improved despite the revenue decline because contribution margins in Xanthine were maintained and cost reductions took hold.
• Pricing disclosure: Management declined to share volume growth or realization data as a practice, but later indicated realization on an average basis would be some 10% to 15% lower in terms of pricing.
• Capacity expansion preference: The company is evaluating several options for further Xanthine capacity and prefers Brownfield expansion over Greenfield to achieve the lowest possible CAPEX and maximum impact, with a 15-18 month timeline once approved.
• Backward integration role: The project to manufacture primary raw material for Xanthine products is set to begin operations in the current quarter, reducing import dependency; management frames it as supply security and insurance against price escalation from China, not a major margin driver in the initial stage.
• Contract structure undisclosed: Management declined to share the proportion of annual vs spot contracts in the Xanthine business or the pricing mechanism when raw material costs change mid-year, citing confidentiality.

Gogri: "It is sort of an insurance for supply commitment at a reasonable price."

API & Intermediate Business

• API dispatch catch-up: Certain product dispatches that did not happen in the prior quarter occurred in the current quarter, though management noted production could do more and some inventory impact remains.
• New block ramp: The new API block is expected to reach almost 70% capacity utilization in FY25; many customers have already approved this block for existing products, and some new products are being validated in H2.
• Multi-purpose block strategy: Higher-volume products are being pushed to the newer block with larger reactors (semi-dedicated asset), freeing up flexible assets for newer product validation and quantity expansion.
• Intermediate business pressure: Intermediates are focused on a newer range of products, partly for captive consumption, with end customers largely regulated; overall pressure is moderate, not very high.
• Domestic revenue decline: Domestic revenue fell 20% QoQ, but management is not concerned because domestic sales include sales to Indian generic companies (Cipla, Glenmark, Dr. Reddy's, Zydus) that ultimately export to regulated markets; Aarti Pharmalabs is more regulated-focused than Aarti Drugs.
• Growth strategy: Management expects the API and intermediate segment to grow as India becomes a more preferred source over Europe and China, with focus on bottom line rather than top line.

Gogri: "We have to do the products which are more profitable and top line actually doesn't matter as much."

CDMO/CMO & R&D Pipeline

• Commercial product growth: The number of commercial products in CMO/CDMO increased by two over the last quarter, and the segment is on course to reach 10% to 12% of overall business revenue.
• API pipeline: Commercialized APIs now stand at 54 (up from 50), with APIs under development at 13 (up from 10); these are at various stages from preclinical through Phase 3, not all late-stage.
• Margin progression: CDMO margins depend on the mix of activities; as the company moves from key starting material to regulated starting material to API, margins improve.
• New R&D lab: A third R&D lab is being set up, recruiting scientists for biotech-related reactions, particularly peptides and other intermediates, with biosimilars and biologics opportunities 2-3 years away.
• Semi-commercial block: A semi-commercial production block at the USFDA intermediate manufacturing site in Vapi will cater to smaller batch sizes (10 kilos to 100 kilos), targeting completion in Q2 FY25.

Subsidiaries & Consolidation

• Joint venture strength: The 50-50 joint venture, a significantly large company with approximately ₹350 crore business, delivered strong numbers this quarter; stable business is expected this year.
• Ganesh Polychem performance: The associate company had a strong quarter driven by higher production and reduction in raw material cost; it makes intermediates used in polymer manufacturing for dialysis/medical grade and other engineering usage.
• Subsidiary ramp-down: Part of the consolidated revenue decline reflects a subsidiary being ramped down, with that business to be routed to Aarti Drugs in a new subsidiary.
• US subsidiary transfer: The US subsidiary will continue to operate for sales, with business transfer to Aarti Industries' own subsidiary expected next financial year.
• Subsidiary EBITDA sustainability: The 18% EBITDA contribution from subsidiaries (including the joint venture) is expected to continue.

CAPEX & Asset Additions

• Hydrogen reactors operational: All nine hydrogen reactors planned for addition in FY24 have been added and are operational; they are in the custom synthesis plant, largely utilized for intermediates and CDMO/CMO products.
• Greenfield project Atali: Significant progress has been made, with a completion target of H2 FY25.
• CAPEX benefit timing: Management expects some benefit from CAPEX ramp-up starting in H2 of this financial year, with more benefit arriving next year.
• Xanthine barrier to entry: The Xanthine business is a regulated business where the approval process is long and facilities must be world-class to meet customer expectations, creating a moat around capacity additions.

Gogri: "Xanthine business is the regulated kind of business where the approval process is long and you need to really have the facilities which are world class to meet the expectations of the customer."

Guidance & Commitments

Key Metrics